News | April 27, 2024
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The proposed facility is expected to be operational around January, 2027
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Sun Pharma's Dadra facility receives OAI status from US FDA
A significant proportion of healthcare professionals still tend to favor branded drugs
Total value of the supplies of FC will be US$ 2.773 million
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The company plans to add 1700 beds by FY27 through the organic route
Subscribe To Our Newsletter & Stay Updated
